Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Ocugen Inc
OCGN | US
2.45
USD0.12
5.15%
OCGN | US
Loading StockChartView...
About Ocugen Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
17/03/2026
Close
2.45
Open
2.46
High
2.72
Low
2.33
Ocugen Inc. a clinical-stage biopharmaceutical company focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400 a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200 a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema diabetic retinopathy and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern Pennsylvania.
View LessOCGN | US
Risk
128.3
Sharpe
4.10
Luna's Score
57/100
Recommendation
Hold
Luna says (OCGN | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
173.5%1 month
128.3%3 months
107.6%6 months
92.6%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
15.22
Price to book
15.82
Debt to equity
0.41
Debt to assets
0.17
Ent. to EBITDA
-1.95
Ent. to rev.
35.65
PEG
-
Other Fundamentals
EBITDA
-50.51M
MarketCap
705.25M
MarketCap(USD)
705.25M
Div. yield
-
Op. margin
-1.35K
Erngs. growth
-
Rev. growth
135.30
Ret. on equity
-114.42
Short ratio
13.03
Short perc.
17.89
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.18
Range1M
1.34
Range3M
1.41
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.80
Price X volume
43.80M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.95 | 0.53 | Cheaper |
| Ent. to Revenue | 35.65 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 15.82 | 15.55 | Par |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 107.57 | 72.80 | Riskier |
| Debt to Equity | 0.41 | -1.23 | Expensive |
| Debt to Assets | 0.17 | 0.25 | Cheaper |
| Market Cap | 705.25M | 3.66B | Emerging |
